Statement by the Executive Chairman

We are ready!

Etienne Jornod

Etienne Jornod
“With their distinct identities, Galenica Santé and Vifor Pharma address shareholders who expect differentiated, high-quality performances, namely continued development with an attractive dividend policy as well as strong growth and a high margin.”

 

 

Dear Shareholders,
Ladies and Gentlemen,

2016 marks a critical new phase in the development of the Galenica Group, with the 21st successive increase in profit in 21 years, excluding the significant impact of the Relypsa acquisition. All activities grew more rapidly than their respective markets.

Major challenges emerged during the course of the year:

  • Needing to strengthen Vifor Pharma management,
  • Finding the right replacement for the reference shareholder Sprint (25.5 % of share capital),
  • Acquiring American company Relypsa,
  • giving Vifor Pharma a real global scale, with a presence and products in the USA,
  • And finally, optimising the market coverage of Galenica Santé by acquiring physicians wholesaler Pharmapool.

These challenges were met to our great satisfaction, once again demonstrating the entrepreneurial spirit and effectiveness of which the entire Galenica Group is capable. The Group is now ready to transform itself into two independent listed companies, each with its own strategy, projects, competences and strengths, as illustrated in the following short profiles.

+13.5 %

profit growth before deduction of minority interests (on a comparable basis, without negative influence of Relypsa and IAS 19)

+2,900 %

cumulative growth in the share price from 1995 (start of the transformation strategy) to 2016


Vifor Pharma

The global leader in iron therapies has built itself a first-rate portfolio of products and projects:

Products and areas each with growth potential of more than one billion Swiss francs over several years:

  • Ferinject®/Injectafer® has already exceeded CHF 500 million (+44 %) in annual sales (IMS)
  • Veltassa®
  • Vifor Fresenius Medical Care Renal Pharma with its products Mircera®, Retacrit™, Velphoro®, etc.


Highly attractive projects with patents due to expire in 2028/34 or later:

  • CCX168 and
  • CCX140, two licences from US company ChemoCentryx
  • RAYALDEE® from American company Opko Health


A range of well-known products that are proven leaders in their respective areas: Venofer®, Maltofer®, Uro-Vaxom®, Broncho-Vaxom®, Doxium®, etc.

 

Galenica Santé

Health partner par excellence in the Swiss market, Galenica Santé is a leader in all its activities:

  • Products & Brands: in the areas of OTC medications and healthcare products;
  • Retail: by the number of points of sale in all regions of Switzerland, and
  • Services: thanks to the highest performing technologies and investments.


A targeted market approach, consolidated year after year for more than two
decades, has enabled Galenica Santé to work in harmony and to create synergies with different players and customers, for each of whom it is also number one, for example:

  • pharmacists, doctors, druggists;
  • pharmaceutical industry, hospitals, nursing homes;
  • consumers and patients through access and supply in its own pharmacy networks, postal consignment or home nursing.

 

The two companies also set themselves apart by their capacity to generate added value through their specific business models and collaborations with leaders in their respective sectors, such as Vifor Pharma with Fresenius Medical Care and Galenica Santé with Coop.
With their distinct identities, Galenica Santé and Vifor Pharma address shareholders who expect differentiated, high-quality performances, namely continued development with an attractive dividend policy as well as strong growth and a high margin.
These companies have been created by first-rate managers and teams, whom I would like to thank for their exceptional commitment on behalf of both the Board of Directors and you, as a shareholder. I believe that you will allow me to take the
liberty to do so.

Bern, 14 March 2017

Contact

Galenica Ltd.

Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 81 11
Fax:
+41 58 852 81 12

Send link

Send as link



Links

  •